There are thus similarities between placebo analgeWe enrolled 15 healthy subjects in a 2 day experiment sia and reward processing, especially as both involve to study the placebo effect on visual emotional proanticipation of a positive outcome and are highly decessing using a set of standardized affective pictures pendent on expectations. The main difference is that (IAPS) (Lang et al., 1995) . On the first day, anxiolytic the concept of a placebo effect involves a reduced and anxiolytic-blocker drugs were used in order to aversion, while the reward concept is associated with modulate the experience of unpleasant pictures. Spea pleasant experience. Here we suggest that placebo cific treatment induced an expectancy effect for the analgesia is actually a special case of reward processdrugs, which is an important factor in the induction of ing, in agreement with recent theoretical considerations a placebo response. On the second day, the subjects (Fields 2004; Vase et al. 2004) . If this is the case, the were treated with the placebo while viewing the same mechanisms underlying the placebo analgesia effect type of unpleasant pictures. The underlying neural remust be viewed as a general process not specifically sponse was simultaneously measured using eventcoupled to pain. We therefore suggest that the placebo related fMRI. phenomenon may be applied to any emotional experience. To test this hypothesis, we probed for placebo Expectation Manipulation on Day 1-Effects effects in the setting of unpleasant emotional experiof Benzodiazepine and Benzodiazepine ence induced by standardized affective pictures. In orAntagonists on Emotional Perception der to generate a strong placebo effect, we induced On day 1, the subjects were shown three presentation a treatment expectation in the group of participating blocks (with a duration of approximately 5 min each) of subjects 1 day prior to the test day using drugs that pseudorandomly mixed unpleasant and neutral pichave well-described specific effects on the emotional tures. The subjects were asked to rate the mean perexperience (anxiolytic drug and blocker of the anxioceived unpleasantness of the viewed unpleasant piclytic drug). This procedure was termed an "expectation tures at the end of each presentation block using a manipulation" in analogy with previous similar active visual analog scale ranging from 0 to 100. After each presentation block, they rated the perceived average unpleasantness induced by the unpleasant pictures using a VAS (range 0-100, where 0 indicated no unpleasantness and 100 indicated maximally imagined unpleasantness). They were first shown a presentation block without treatment (presentation 1; mean rating of unpleasantness = 51.0). In the second condition, the subjects were treated with the anxiolytic drug midozalam, 0.015 mg/kg intravenously, before the presentation block (presentation 2; mean rating of unpleasantness = 29.0). In the third condition, the subjects were treated with 0.25 mg of flumazenil intravenously before the third presentation block (presentation 3; mean rating of unpleasantness = 60.9). (B) On day 2, the subjects underwent the placebo fMRI experiment (placebo manipulation). The experiment was divided between three sessions consisting of two presentation blocks each presented in a semirandom order (see Experimental Procedures). Before the three presentation blocks, the subjects were informed that they would receive the same anxiolytic substance as on day 1 (placebo condition). However, they received 5 ml of saline intravenously instead. The mean rating of unpleasantness of the placebo sessions was 36.4. The subjects were informed that they would receive the anxiolytic blocker before the other presentation blocks (control condition). The mean rating of the induced unpleasantness during the control conditions was 50.9. There was a significant difference between the unpleasantness ratings in the placebo versus the control condition (p < 0.001; Wilcoxon's Signed Rank test). tion (presentation block 2; unpleasantness rating = menced. However, instead of being treated with the active drugs, the subjects received intravenous saline 29.0; range = 8-52) ( Figure 1A ). This effect was completely reversed in the third presentation (presentation before each presentation block. Thus, when the subjects thought that they had received the anxiolytic drug, block 3; unpleasantness rating = 60.9; range = 25-88) for all subjects by pretreating them intravenously with the placebo effect was induced (expectation of anxiolytic effect), and when the subjects thought that they a benzodiazepine receptor antagonist (flumazenil, 0.25 mg) ( Figure 1A) . The subjects were informed of the poshad received the anxiolytic blocker, the control effect was induced (no expectation of anxiolytic effect). The sible effect of the anxiolytic and the anxiolytic blocker drugs on their perception of emotions before the experfMRI study incorporated three sessions, each session including one presentation block consisting of ten uniment and before each picture presentation block. Thus, on the first day a robust expectation of the treatpleasant and ten neutral pictures following the placebo treatment (with a duration of approximately 4 min) and ment effect was induced (i.e., the experience of the drug treatment and the given information), which is an one similar presentation block following control treatment ( Figure 1B) . Four different event-related condiimportant component in the placebo response. The subjects were further told that both the anxiolytic drug tions were therefore induced in a factorial design: (1) unpleasant pictures after placebo treatment (UP); (2) and the anxiolytic blocker would be used again on day 2 in the fMRI experiment. neutral pictures after placebo treatment (NP); (3) unpleasant pictures after control treatment (UC); and (4) neutral pictures after control treatment (NC).
Placebo Manipulation on Day 2-Effects of Placebo on Emotional Perception
There was a significant and robust placebo response for the whole group in that viewing of the unpleasant On day 2, the subjects underwent the event-related fMRI study of the placebo effect on emotional processpictures yielded a 28.6% decrease in the VAS rating of unpleasantness for the placebo conditions as coming. The subjects were told that they would be treated either with the same anxiolytic drug or the anxiolytic pared to control conditions (unpleasantness rating in UC condition = 50.9; and in UP condition = 36.4; p < blocker prior to presentation of unpleasant and neutral pictures as during the previous day. They were also ex- Our first specific analysis concerned the question of whether there was a placebo-related attenuation in the response of the emotional network. In accordance with the behavioral data, the activity in several areas of the extrastriate visual areas was significantly decreased in the placebo condition compared with the blocker condition for the unpleasant pictures ( Figure 2B ; Tables 2  and 3 ). The effect was apparent for both the group consisting of all subjects and for the subgroup of placebo 
Modulatory Network underlying the Placebo Effect
The main focus of this study was the modulatory neting placebo as compared to control sessions. We work involved in the general placebo response, includtherefore classified 11 subjects as responders and the ing the lObfc and the rACC. The right lObfc was acti-4 others as nonresponders.
vated when placebo was compared with the control treatment after adjusting for nonspecific effects in the interaction analysis [(UP − UC) − (NP − NC)], even in Effects of Placebo on Emotional Processing
The fMRI data demonstrated an increased activity in a the group comprising all subjects ( Figure 3B ; Tables 2  and 3 ). This effect was also evident for the whole group visual emotional network including the extrastriate cortex and the amygdala in response to the emotional picin the simple main effect of (UP − UC). Thus, the right 
hemisphere activation of the lObfc, previously shown in unpleasantness rating due to placebo treatment that was reported after the fMRI session ( Figure 4A and Ta jective placebo effect, even at an exploratory low threshold (p < 0.05, uncorrected).
Correlation Analysis between Neuronal Activity and Treatment Expectation
Similar to the placebo effect, the treatment expectation for the specific treatment correlated with nonspecific placebo-dependent decreases in the extrastriate cortex ( Figure 6A and Table 5 ). The degree of decrease in extrastriate activity during the placebo treatment (UC − UP) observed during day 2 was most apparent in those subjects that had the largest effect with the anxiolytic treatment on the emotional experience on day 1. A correlation was also determined between the placebo-dependent increase in rACC and the treatment expectation ( Figure 6B and Table 5 ), i.e., subjects that had the strongest effect of the specific anxiolytic treatment on emotional experience day 1 also had the most expressed placebo-dependent activation of the rACC Table 5 ). regions of the ACC and vlPFC in (UP − UC) ( Figure 4B and Table 4 ). Thus, subjects that reported the largest decreases in unpleasantness after the placebo treatDiscussion ment also had the most extensive placebo-dependent activation of the ACC. However, Obfc activation in The present data demonstrate that emotional experience may be modulated through a placebo treatment (UP − UC) did not show any correlation with the sub- However, as stated above, there was a distinction between the lObfc and the rACC in that only the activation of the latter correlated with the subjective placebo response. This response was expressed somewhat more caudally in the rACC than in the subtraction analysis. Finally, the vlPFC showed bilateral placebo-dependent activation in both the subtraction analysis for the placebo responders and also correlated positively with the subjective placebo response. The behavioral placebo effect has been shown to be highly dependent on the treatment expectancy that has previously been induced, either through experimental in the ACC on day 2 (Figures 6A and 6B) . These findings indicate that the preceding anxiolytic treatment also cebo effect (Vase et al., 2004 ). We only used the effect of treatment on day 1 as a measurement of treatment predicts the placebo effect at a neuronal level and that the relationship between the expectation and the plaexpectation so we did not know exactly what the subjects expected before treatment on day 2. However, we cebo response is not simply a behavioral response bias. It should be noted that treatment expectations avoided direct rating of treatment expectation since it could have induced a suspicion in the subjects that a were only indirectly measured in the present study. The active substance and the suggestions on days 1 and 2 nonactive agent was actually used (although such measurements have been successfully used previously probably all induced expectations underlying the pla- 5 ml saline during 10 s. The subjects were told that the treatment consisted of a short-lasting anxiolytic drug and that they would Experimental Procedures probably perceive the pictures as less unpleasant. Before the final presentation (presentation block 3), the subjects received a clinical Fifteen female subjects (age ranging from 20 to 33 years) comdose of a benzodiazepine receptor antagonist intravenously (flupleted this 2 day study. They were all right handed according to the mazenil; manufactured by Roche; manufacturing name = Lanexat; Edinburgh handedness inventory. They had no history of any major concentration = 0.1 mg/ml; dose = 0.25 mg; rate of infusion = psychiatric or neurological conditions. All subjects were healthy 10 s). They were told that this treatment would act as an antidote and took no medications, except for one allergic subject who used and completely block the effect of the anxiolytic drug. Injection of a mild asthma inhalation medicine. However, we did not account the active substance was followed by a flush with 5 ml saline durfor either menstrual phase or birth control. All subjects gave their ing 10 s. informed consent. The study was approved by the local ethics The subjects were fully informed about the three sessions before committee at Karolinska University Hospital. the start of the experiment. There was an approximate time lag of 10 min between each presentation block. After each presentation block, the subjects rated their average unpleasantness level for the Stimuli Neutral and unpleasant images from the international affective picunpleasant pictures using a visual analog scale (VAS) ranging from 0 to 100, where 0 denoted no unpleasantness and 100 the highest ture system (IASP) (Lang et al., 1995) were shown in different presentation blocks. Each picture was presented for 4 s. There was a imaginable unpleasantness perception. The scale consisted of a 10 cm long line (printed on paper) that the subjects marked with a delay of 7 s between the pictures during which a black screen with a cross was presented. During the fMRI experiment, there was also cross depending on their rating. A cross that was placed 1 cm from the start of the line was interpreted as 10 on the VAS. During the a jitter added in the delay period, and the stimulus onset asynchronicity was then 11, 12.2, or 13.4 s, respectively. The subjects were first day, the subjects also completed personality and mood questionnaires. These data are not presented in this article due to lack instructed to focus on the cross between the pictures and to continue to focus centrally during the picture presentation. of space. In presentation block 2, the anxiolytic treatment decreased the During day 1, there were three different versions of picture presentation blocks. These were randomly assigned to presentation rating of unpleasantness by 43.1% compared to presentation block 1 in which the subjects did not receive any treatment. The effect of block 1, 2, or 3, respectively, for each participant. Thus, there were no systematic differences in presented pictures for the whole group the anxiolytic blocker was a less-expressed increase in the rating of unpleasantness (19.5%; presentation block 3 versus presentabetween the presentations in which the subjects were untreated (presentation block 1), the presentation in which the subjects retion block 1). Thus, although both the anxiolytic and the anxiolytic blocker treatment may have induced expectations, the effect domiceived an anxiolytic treatment (presentation block 2), or the presentation in which the subjects were treated with the anxiolytic nated after the anxiolytic treatment. The degree of expectation has been shown to be fundamental for the placebo effect (Price et al., blocker (presentation block 3).
During the fMRI experiment (day 2), six separate presentation 1999). We therefore considered that the anxiolytic treatment induced the most extensive placebo effect, although the blocker blocks were used for the three sessions (two presentation blocks in each session, one with the placebo treatment and one with the condition probably also induced a small negative placebo (or nocebo) effect. For simplicity, we have termed the placebo manipulacontrol treatment). The order of presentation blocks (1 to 6) was randomly assigned for each subject.
tion associated with the anxiolytic drug as the "placebo treatment," and the nocebo manipulation associated with the anxiolytic blocker Each presentation block consisted of 13 unpleasant and 13 neutral pictures on the first day and 10 unpleasant and 10 neutral picas the "control treatment." On day 2, a placebo manipulation was performed, and the subtures on the second day (i.e., in the fMRI experiment). The pictures were semirandomly distributed (using a computerized randomizing jects simultaneously underwent fMRI scanning ( Figure 1B) . The functional scanning consisted of three sessions of two presentaprocess) in that pictures from the same category were not allowed to appear more than three times in a row in order to avoid habituation blocks each (i.e., six presentation blocks in total). Each presentation block contained the same type of unpleasant and pleastion effects. Each presentation block included a balanced number of pictures showing mutilated bodies. There was an uneven distriant pictures as was shown on day 1, during a period of 4 min and 6.4 s. The subjects were informed that they would be given the bution of faces in the negative (n = 6-7 per session on day 1 and 7-8 per session on day 2) versus the positive pictures (n = 0-1 per same pharmacological treatment as on the previous day before each new presentation block (i.e., the anxiolytic or the anxiolytic session). Some of the activity in the emotional network was thus biased toward face processing. However, no such bias existed in blocker treatment). They were also told that the effect of each treatment was only short lasting and that they would therefore be the contrasts of interest (i.e., the placebo contrasts), since these presentations contained a balanced number of neutral and negatreated several times with each drug. Finally, they were informed that the anxiolytic drug could override the effects of the anxiolytic variance in latency. A high-pass filter was used to remove lowfrequency noise. blocker in the same way that the blocker could suppress the effects of the anxiolytic drug. An information text indicating the forthAll contrasts were first analyzed for each individual using SPM99. We then made three different second-level analyses of the eventcoming treatment and its probable result on emotional perception was exhibited before each presentation on a computer screen in related fMRI data using a random-effects model of one-sample t tests in SPM99, thereby implementing a random-effects analysis order to induce a strong expectation of the drug effect. As on day 1, the subjects had an intravenous catheter, and they could clearly through the summary statistic approach. In the first analysis, we considered the whole group in order to find effects that were appliperceive when the "drug" was administered, i.e., when it was flushed with saline. As the information was presented for 52 s, 5 ml cable to the population in general and that would support the behavioral data for the whole group. The second analysis was applied saline was simultaneously injected intravenously. The rate of injection and the volume was the same as during day 1 for each specific specifically to the placebo responders, which may be more relevant for the mechanisms involved in the effective placebo response. The substance and saline flush. Each experiment was comprised of three presentation blocks of neutral and unpleasant pictures in third analysis looked at correlations between the subjective degree of placebo response (reported in the debriefing session, i.e., rating which expectation of anxiety relief was induced (placebo condition) and three similar presentation blocks in which no such expectation of unpleasantness for the unpleasant pictures after the control versus the placebo treatment) and activations due to placebo. A simwas present, but possibly a small negative expectation, i.e., nocebo (control condition). There were two orders (A and B) of the ilar correlation analysis was performed for the treatment expectations. conditions in the three sessions that were randomly assigned to the different subjects:
All subjects took part in the group analysis, while 11 were included in the analysis for the subgroup of placebo responders. In the correlation analysis, one of the 15 subjects could not be in- regions that are involved in emotional processing and that we expected to be attenuated in the placebo condition. To ensure that Thus, some subjects began with the control condition in order to all the regions belonged to the network involved in emotional proavoid order effects in the group analysis. All subjects were incessing, they also had to survive a masking in the main effect of formed that it was possible to begin with the anxiolytic blocker emotion contrast (UP + UC) − (NP + NC) set at a threshold of p < condition because of order effects (which is not intuitive) and to 0.05 (uncorrected). In the contrasts of (UP − UC) and the interaction avoid induction of any surprise during the experiment. The reanalysis of ((UP − UC) − (NP − NC)), we included the rACC, the searcher injecting the saline was not aware of the order of the conlObfc/vlPFC, and the ventral striatum in our a priori defined network ditions. As stated above (see "Stimuli"), the order of the six dif-(the reasoning why these regions are included is stated in the core ferent picture presentation blocks was randomized for each text). We report all activations surviving a threshold of uncorrected subject. After the fMRI sessions, each subject underwent a debriefp value < 0.005 in these regions and their t values. ing session and rated their average unpleasantness level (VAS-as explained above) elicited by the unpleasant pictures after treatment Acknowledgments with the anxiolytic (i.e., placebo) drug and anxiolytic blocker (i.e., control) drug. Each subject also had to indicate verbally whether 
